SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma

Neoplasia (United States)

Volumn 16, Issue 7, 2014, Pages 572-585

  Noll, Jacqueline E ^a,b   Hewett, Duncan R ^a,b   Williams, Sharon A ^a,b   Vandyke, Kate ^a,b   Kok, Chung ^b   To, Luen B ^b   Zannettino, Andrew C W ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928767798     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.07.002     Document Type: Article

References (47)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Brenner H., Gondos A., Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009, 94:270-275.
3. Weiss B.M., Abadie J., Verma P., Howard R.S., Kuehl W.M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009, 113:5418-5422.
4. Rajkumar S.V., Kyle R.A., Buadi F.K. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010, 85:945-948.
5. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002, 346:564-569.
6. Fonseca R., Bergsagel P.L., Drach J., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221.
7. Facon T., Avet-Loiseau H., Guillerm G., et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001, 97:1566-1571.
8. Jenner M.W., Leone P.E., Walker B.A., et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007, 110:3291-3300.
9. Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
10. Fonseca R., Van Wier S.A., Chng W.J., et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006, 20:2034-2040.
11. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101:4569-4575.
12. Keats J.J., Reiman T., Maxwell C.A., et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003, 101:1520-1529.
13. Davies F.E., Dring A.M., Li C., et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003, 102:4504-4511.
14. Lopez-Corral L., Gutierrez N.C., Vidriales M.B., et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res 2011, 17:1692-1700.
15. Walker B.A., Wardell C.P., Chiecchio L., et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011, 117:553-562.
16. Radl J., Croese J.W., Zurcher C., Van den Enden-Vieveen M.H., de Leeuw A.M. Animal model of human disease. Multiple myeloma. Am J Pathol 1988, 132:593-597.
17. Radl J., De Glopper E.D., Schuit H.R., Zurcher C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 1979, 122:609-613.
18. Claudio J.O., Zhu Y.X., Benn S.J., et al. HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells. Oncogene 2001, 20:5373-5377.
19. Wang D., Stewart A.K., Zhuang L., et al. Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1. FASEB J 2010, 24:947-956.
20. Zhu Y.X., Benn S., Li Z.H., et al. The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades. J Exp Med 2004, 200:737-747.
21. Yamada H., Yanagisawa K., Tokumaru S., et al. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chromosomes Cancer 2008, 47:810-818.
22. Davey R.A., Hahn C.N., May B.K., Morris H.A. Osteoblast gene expression in rat long bones: effects of ovariectomy and dihydrotestosterone on mRNA levels. Calcif Tissue Int 2000, 67:75-79.
23. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
24. Diamond P., Labrinidis A., Martin S.K., et al. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res 2009, 24:1150-1161.
25. Rayner J.R., Gonda T.J. A simple and efficient procedure for generating stable expression libraries by cDNA cloning in a retroviral vector. Mol Cell Biol 1994, 14:880-887.
26. Isenmann S., Arthur A., Zannettino A.C., et al. TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment. Stem Cells 2009, 27:2457-2468.
27. Chesi M., Robbiani D.F., Sebag M., et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008, 13:167-180.
28. Radl J., Hollander C.F., van den Berg P., de Glopper E. Idiopathic paraproteinaemia. I. Studies in an animal model-the ageing C57BL/KaLwRij mouse. Clin Exp Immunol 1978, 33:395-402.
29. Fowler J.A., Mundy G.R., Lwin S.T., Lynch C.C., Edwards C.M. A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis Model Mech 2009, 2:604-611.
30. Garrett I.R., Dallas S., Radl J., Mundy G.R. A murine model of human myeloma bone disease. Bone 1997, 20:515-520.
31. Oyajobi B.O., Munoz S., Kakonen R., et al. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 2007, 6:1701-1708.
32. Vanderkerken K., De Raeve H., Goes E., et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997, 76:451-460.
33. Fowler J.A., Lwin S.T., Drake M.T., et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood 2011, 118:5872-5882.
34. Noll J.E., Williams S.A., Tong C.M., et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica 2013, 99:163-171.
35. Heller G., Schmidt W.M., Ziegler B., et al. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 2008, 68:44-54.
36. Cashman J., Eaves A.C., Eaves C.J. Regulated proliferation of primitive hematopoietic progenitor cells in long-term human marrow cultures. Blood 1985, 66:1002-1005.
37. Hurley R.W., McCarthy J.B., Verfaillie C.M. Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest 1995, 96:511-519.
38. Lwin T., Hazlehurst L.A., Dessureault S., et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 2007, 110:1631-1638.
39. Mitelman F., Mertens F., Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 1997, 15:417-474. [Spec No].
40. Ni I.B., Ching N.C., Meng C.K., Zakaria Z. Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study. Hematol Rep 2012, 4:60-65.
41. Kassambara A., Hose D., Moreaux J., et al. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica 2012, 97:622-630.
42. Bollati V., Fabris S., Pegoraro V., et al. Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis 2009, 30:1330-1335.
43. Heuck C.J., Mehta J., Bhagat T., et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol 2013, 190:2966-2975.
44. von Holleben M., Gohla A., Janssen K.P., Iritani B.M., Beer-Hammer S. Immunoinhibitory adapter protein Src homology domain 3 lymphocyte protein 2 (SLy2) regulates actin dynamics and B cell spreading. J Biol Chem 2011, 286:13489-13501.
45. Levesque J.P., Zannettino A.C., Pudney M., et al. PSGL-1-mediated adhesion of human hematopoietic progenitors to P-selectin results in suppression of hematopoiesis. Immunity 1999, 11:369-378.
46. Kim C.A., Bowie J.U. SAM domains: uniform structure, diversity of function. Trends Biochem Sci 2003, 28:625-628.
47. Zarrinpar A., Bhattacharyya R.P., Lim W.A. The structure and function of proline recognition domains. Sci STKE 2003, re8:1-10.